Reforgene again named a Guangzhou Future Unicorn enterprise

Recently, the 2023 Guangzhou International Innovation Festival was grandly held at the Guangzhou Library. At the opening ceremony of the conference, the highly anticipated unicorn innovative enterprise list was officially unveiled. Reforgene was successfully selected as a "Future Unicorn Innovative Enterprise", its second consecutive year receiving this honor.

The 2023 Guangzhou Unicorn innovative enterprise list is an authoritative list guided by the Guangzhou Municipal Science and Technology Bureau and jointly hosted and released by the Guangzhou Industrial Development Research Institute, the Guangzhou Science and Technology Innovation Enterprises Association and PwC China, aiming to identify innovative enterprises with strong innovation, fast growth and great development potential, cultivate future leading innovative enterprises, and give play to their innovation-leading and demonstration roles.

In recent years, cell and gene therapy has developed rapidly and has become one of the most promising directions in the biomedical field. Reforgene is dedicated to the development of innovative gene editing medicines. With its continuously deepening underlying technology innovation capability and excellent talent team, it has pipeline programs in hematology, ophthalmology, liver and central nervous system fields, achieving notable progress.

Recently, Reforgene announced that its independently developed beta-thalassemia gene editing medicine RM001 (HBG gene-modified autologous CD34+ hematopoietic stem cell injection) has achieved leading excellent efficacy, with Phase I clinical trials nearing completion and Phase II clinical trials planned for 2024.

Being listed again as a "Future Unicorn Innovative Enterprise" is both an honor and an encouragement. Reforgene will not forget its original aspiration and will forge ahead, upholding the mission of "Innovation for Life", deeply cultivating underlying gene editing technology and drug R&D, and dedicating itself to developing curative medicines for serious diseases, so that cutting-edge biotechnology benefits human health.